Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)
Yuan Tian(Shandong Provincial QianFoShan Hospital), Simone Filosto(Kite (United States)), Frederick L. Locke(Moffitt Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Gayatri Tiwari, Daqin Mao(Tufts Medical Center), Justin A. Budka(Gilead Sciences (United Kingdom)), Davide Bedognetti(Sidra Medical and Research Center), Rhine R. Shen(Broad Institute), Christina To, Jorge Andrade(University of Chicago)
Cited by 2
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k